Tonghua Dongbao Pharmaceutical Co.,ltd
Clinical trials sponsored by Tonghua Dongbao Pharmaceutical Co.,ltd, explained in plain language.
A Chinese pharmaceutical company focused on diabetes and endocrine drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New insulin candidate tested in 1,040 chinese diabetes patients
Disease control CompletedThis study tested a new insulin called THDB0206 against a standard insulin (lispro) in 1,040 Chinese adults with type 2 diabetes. Both were used alongside a long-acting insulin. The goal was to see if the new insulin works as well or better at controlling blood sugar over 26 week…
Phase: PHASE3 • Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New insulin shows promise for type 1 diabetes in chinese trial
Disease control CompletedThis Phase 3 trial tested a new fast-acting insulin called THDB0206 against a standard insulin (lispro) in 550 Chinese adults with type 1 diabetes. Both groups also used a long-acting insulin (glargine). The main goal was to see if THDB0206 could control blood sugar (HbA1c) as we…
Phase: PHASE3 • Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Where you inject matters: new study tests insulin at three sites
Knowledge-focused CompletedThis completed Phase 1 study looked at how a single dose of the insulin drug THDB0206 behaves when injected into the upper arm, abdomen, or thigh. Twenty-seven healthy Chinese adults each received the same dose at all three sites in a random order. The goal was to see if the inje…
Phase: PHASE1 • Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC